OraSure Technologies, Inc. (NASDAQ:OSUR) has earned an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $14.89.
Several analysts recently commented on OSUR shares. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Saturday, May 6th. Jefferies Group LLC boosted their price objective on shares of OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, May 4th. Canaccord Genuity boosted their price objective on shares of OraSure Technologies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, June 28th. Finally, Stephens reissued an “overweight” rating and issued a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th.
ILLEGAL ACTIVITY WARNING: “OraSure Technologies, Inc. (OSUR) Given Average Rating of “Buy” by Brokerages” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/07/22/orasure-technologies-inc-osur-given-average-rating-of-buy-by-brokerages.html.
In related news, CEO Douglas A. Michels sold 290,495 shares of the stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $16.75, for a total value of $4,865,791.25. Following the sale, the chief executive officer now directly owns 894,012 shares of the company’s stock, valued at approximately $14,974,701. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Douglas A. Michels sold 361,216 shares of the stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $15.08, for a total transaction of $5,447,137.28. Following the completion of the sale, the chief executive officer now directly owns 881,620 shares in the company, valued at $13,294,829.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,220,134 shares of company stock worth $18,789,795. Corporate insiders own 7.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OSUR. Victory Capital Management Inc. purchased a new position in OraSure Technologies during the first quarter worth about $100,000. Private Advisor Group LLC raised its position in OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 723 shares during the period. Profund Advisors LLC purchased a new position in OraSure Technologies during the first quarter worth about $137,000. BNP Paribas Arbitrage SA raised its position in OraSure Technologies by 977.2% in the first quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 9,723 shares during the period. Finally, Capital Fund Management S.A. purchased a new position in OraSure Technologies during the first quarter worth about $144,000. Institutional investors own 88.23% of the company’s stock.
Shares of OraSure Technologies (OSUR) traded down 1.96% on Monday, reaching $18.00. 873,906 shares of the company’s stock were exchanged. OraSure Technologies has a one year low of $6.37 and a one year high of $19.33. The firm has a 50 day moving average of $16.71 and a 200 day moving average of $12.95. The firm has a market capitalization of $1.04 billion, a P/E ratio of 34.48 and a beta of 1.57.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 EPS for the quarter, beating the consensus estimate of $0.17 by $0.04. OraSure Technologies had a net margin of 22.57% and a return on equity of 16.06%. The firm had revenue of $32.55 million during the quarter, compared to the consensus estimate of $31.19 million. During the same quarter in the prior year, the firm earned $0.04 EPS. OraSure Technologies’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, equities research analysts predict that OraSure Technologies will post $0.43 EPS for the current year.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.